


This is a preview of "NSF/ANSI 455-4-2020". Click here to purchase the full version from the ANSI store.



*NSF International Standard /
American National Standard*

NSF/ANSI 455-4 - 2020

Good Manufacturing Practices
for Over-the-Counter Drugs



NSF International, an independent, not-for-profit, nongovernmental organization, is dedicated to being the leading global provider of public health and safety-based risk management solutions while serving the interests of all stakeholders.

This Standard is subject to revision.
Contact NSF to confirm this revision is current.

Users of this Standard may request clarifications and interpretations, or propose revisions by contacting:

Chair, Joint Committee on Good Manufacturing Practices for Over-the-Counter Drugs
c/o NSF International
789 North Dixboro Road, PO Box 130140
Ann Arbor, Michigan 48113-0140 USA
Phone: (734) 769-8010 Fax: (734) 769-0109
Email: info@nsf.org
Web: www.nsf.org

NSF/ANSI 455-4 – 2020

NSF International Standard /
American National Standard
for Good Manufacturing Practices –
**Good Manufacturing Practices
for Over-the-Counter Drugs**

Standard Developer
NSF International

Designated as an ANSI Standard
April 10, 2020
American National Standards Institute

Prepared by
The NSF Joint Committee on Good Manufacturing Practices for Over-the-Counter Drugs

Recommended for Adoption by
The NSF Council of Public Health Consultants

Adopted by
NSF International
November 2018

Revised November 2020

Published by
NSF International
PO Box 130140, Ann Arbor, Michigan 48113-0140, USA

For ordering copies or for making inquiries with regard to this Standard, please reference the designation
"NSF/ANSI 455-4 – 2020."

Copyright 2020 NSF International

Previous editions © 2018

Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from NSF International.

Printed in the United States of America.

Disclaimers¹

NSF International (NSF), in performing its functions in accordance with its objectives, does not assume or undertake to discharge any responsibility of the manufacturer or any other party. The opinions and findings of NSF represent its professional judgment. NSF shall not be responsible to anyone for the use of or reliance upon this Standard by anyone. NSF shall not incur any obligation or liability for damages, including consequential damages, arising out of or in connection with the use, interpretation of, or reliance upon this Standard. It is the responsibility of the user of this standard to judge the suitability of the ANS for the user's purpose.

NSF Standards provide basic criteria to promote sanitation and protection of public health and the environment. Provisions for mechanical and electrical safety have not been included in this Standard because governmental agencies or other national standards-setting organizations provide safety requirements.

Participation in NSF Standards development activities by regulatory agency representatives (federal, state, or local) shall not constitute their agency's endorsement of NSF or any of its Standards.

Preference is given to the use of performance criteria measurable by examination or testing in NSF Standards development when such performance criteria may reasonably be used in lieu of design, materials, or construction criteria.

The illustrations, if provided, are intended to assist in understanding their adjacent standard requirements. However, the illustrations may not include all requirements for a specific product or unit, nor do they show the only method of fabricating such arrangements. Such partial drawings shall not be used to justify improper or incomplete design and construction.

At the time of this publication, examples of programs and processes were provided for general guidance. This information is given for the convenience of users of this standard and does not constitute an endorsement by NSF International. Equivalent programs and processes may be used.

Unless otherwise referenced, the annexes are not considered an integral part of NSF Standards. The annexes are provided as general guidelines to the manufacturer, regulatory agency, user, or certifying organization.

¹ The information contained in this Disclaimer is not part of this American National Standard (ANS) and has not been processed in accordance with ANSI's requirements for an ANS. Therefore, this Disclaimer may contain material that has not been subjected to public review of a consensus process. In addition, it does not contain requirements necessary for conformance to the Standard.

This page is intentionally left blank.

Contents

1	General	1
1.1	Purpose.....	1
1.2	Scope.....	1
2	Normative references	2
3	Definitions	5
4	Audit requirements.....	5
4.1	Context of the organization.....	5
4.2	Leadership	5
4.3	Planning	6
4.4	Support	6
4.5	Operation	9
4.6	Performance evaluation	12
4.7	Improvement.....	13
5	Audit process	14
5.1	Audit process introduction	14
5.2	Audit and certification process outline	14
5.3	Audit preparation.....	15
5.4	Audit planning	17
5.5	On-site audit.....	19
5.6	Reporting / grading	22
5.7	Nonconformances and corrective action	23
5.8	Post audit activities	24
Informative Annex 1 Additional elements of a certification program for GMP for over-the-counterdrugs (OTC)..... 27		
I-1.1	General.....	27
I-1.2	ANSI approved Mark use, marketing and references to the Standard.....	27
I-1.3	Resource requirements – Competence of personnel.....	27
I-1.4	Process requirements.....	28
I-1.5	Listing certified companies	29
I-1.6	Appeals.....	29
I-1.7	Complaints.....	29
I-1.8	Advertising	30
I-1.9	Confidentiality	30
I-1.10	References	30

This page is intentionally left blank.

Foreword²

The purpose of NSF/ANSI 455-4 is to serve as an evaluation tool for analyzing good manufacturing practices (GMP) for over-the-counter (OTC) drug manufacturers. Certification to this Standard serves as a communication tool between manufacturers of OTC drugs, regulators, retailers, and consumers.

This edition of the Standard contains the following revisions:

Issue 13

This revision harmonizes the numbering in Sections 4.2 and 4.3 to that of NSF/ANSI 455-2, *Good Manufacturing Practices for Dietary Supplements*, and NSF/ANSI 455-3, *Good Manufacturing Practices for Cosmetics*, under the ISO Format.

Issue 14

This revision rewords language in Sections 4.2.2 and 4.8.2.

Issue 15

This revision harmonizes the numbering in Section 4.4 to that of NSF/ANSI 455-2, *Good Manufacturing Practices for Dietary Supplements*, and NSF/ANSI 455-3, *Good Manufacturing Practices for Cosmetics*, under the ISO Format.

Issue 17

This revision will add more clarity in Section 4.7.15 on what is required for traceability and mock recalls.

Issue 19

This revision harmonizes the language in Section 5.2 to that of NSF/ANSI 455-2, *Good Manufacturing Practices for Dietary Supplements*, and NSF/ANSI 455-3, *Good Manufacturing Practices for Cosmetics*, under the ISO Format.

Issue 22

This revision harmonizes the language in Section 5.7.3 to that of NSF/ANSI 455-2, *Good Manufacturing Practices for Dietary Supplements*, and NSF/ANSI 455-3, *Good Manufacturing Practices for Cosmetics*, under the ISO Format.

This Standard was developed by the NSF Joint Committee on Good Manufacturing Practices for Over-the-Counter Drugs using the consensus process described by the American National Standards Institute, and with participation from over-the-counter drug manufacturers, public health regulators, and consumers and retailers of over-the-counter drugs.

Suggestions for improvement of this Standard are welcome. This Standard is maintained on a continuous maintenance schedule and can be opened for comment at any time. Comments should be sent to Chair, Joint Committee on Good Manufacturing Practices for Over-the-Counter Drugs at standards@nsf.org, or c/o NSF International, Standards Department, PO Box 130140, Ann Arbor, Michigan 48113-0140, USA.

² The information contained in this Foreword is not part of this American National Standard (ANS) and has not been processed in accordance with ANSI's requirements for an ANS. Therefore, this Foreword may contain material that has not been subjected to public review of a consensus process. In addition, it does not contain requirements necessary for conformance to the Standard.

This page is intentionally left blank.

NSF/ANSI Standard for Good Manufacturing Practices –

Good Manufacturing Practices for Over-the-Counter Drugs

1 General

1.1 Purpose

The principles outlined in this Standard provide a comprehensive basis for the quality management system used in the manufacture of over-the-counter (OTC) drugs. Implementation of these principles shall result in the achievement of three main objectives:

- **achieve OTC drug realization:** the organization shall implement and maintain a system that delivers OTC drugs with the quality attributes necessary to meet the requirements and expectations of customers, retailers, and regulatory authorities;
- **establish and maintain a state of control:** the organization shall ensure the manufacture and supply of OTC drugs is in accordance with this Standard, thus providing customers with some assurance of continued suitability and reliability of supply; and
- **facilitate continual improvement:** the organization shall collect objective evidence to continually develop and enhance the application of these quality management system principles to further assure OTC drug consistency.

1.2 Scope

This Standard is intended to define a standardized approach for auditing to determine the level of compliance of over-the-counter (OTC) drug products to 21 CFR Part 210 *Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General* and 21 CFR Part 211 *Current Good Manufacturing Practice for Finished Pharmaceuticals*, well as incorporating additional retailer requirements. It refers to the requirements for good manufacturing practices (GMPs) applicable to all OTC drugs. It will assist in the determination of adequate facilities and controls for OTC drug manufacture with sufficient quality to ensure suitability for intended use.